Buy ADB Fubinaca White Research Chemical Powders

Adb -Fubinaca White Powder C21H23FN4O2 Cas 1445583-51-6 High Purity 98%

ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.

An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.

ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of theCB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesicmedication.[1][2] It was identified in cannabinoid blends in Japan in early 2015

5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug.[1][2]

5F-AB-PINACA has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.48 nM and 2.6 nM respectively.[3] Its metabolism has been described in literature.

AB-CHMINACA is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor(Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and fully substitutes for Δ9-THC in rat discrimination studies, while being 16x more potent.[1][2] Continuing the trend seen in other cannabinoids of this generation, it contains a valine amino acid amide residue as part of its structure, where older cannabinoids contained a naphthyl or adamantane residue.

MDMB-CHMICA (also incorrectly known as MMB-CHMINACA) is an indole-based synthetic cannabinoidthat is a potentagonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name “MMB-CHMINACA”, the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

Ergotamine is an and part of the family o; it is structurally and biochemically closely related to It possesses structural similarity to several and has as a

It is used for treatment of acute attacks (sometimes in combination with Medicinal usage of ergot fungus began in the 16th century to induce yet dosage uncertainties discouraged the use. It has been used to prevent (bleeding after childbirth). It was first isolated from the ergot fungus and marketed as Gynergen in 1921

N-Ethylhexedrone (also known as α-ethylaminocaprophenone, N-ethylnorhexedrone, hexen andNEH) is of the classN-Ethylhexedrone was first mentioned in a series of patents byin the 1960s which lead to the development of the better known drug (MDPV). Since the mid-2010s, N-ethylhexedrone has been sold online

Fuambai Sia Ahmadu (born c. 1969 is a Sierra Leonean-American anthropologist. She has worked for and the British lin the Gambia.

Ahmadu obtained her PhD in social anthropology from the and undertook post-doctoral work at the Department of Comparative Human Development,

FUF

Fentanyl provides some of the effects typical of other opioids through its agonism of the . Its strong potency in relation to that of morphine is largely due to its highper the Because of this, it can more easily penetrate the

BROMADOLINE is the same effect with u-47700

Alprazolam is mostly used to treat and due to The FDA label advises that the physician should periodically reassess the usefulness of the drug. Alprazolam may also be indicated for the treatment of generalized anxiety disorder, as well as for the treatment of anxiety conditions with co-morbid depression. Alprazolam is also often prescribed with instances co-morbid sleep deficits.

α-PVP, like other psychostimulants, can cause hyperstimulation, paranoia, and hallucinations. α-PVP has been reported to be the cause, or a significant contributory cause of death in suicides and overdoses caused by combinations of drugs. α-PVP has also been linked to at least one death where it was combined with and caused